Nanobiotix Shares Drop 5.66% Despite a 612% Rally Over the Year

Recent Performance and Technical Indicators

Nanobiotix's stock has declined by 5.83% over the past seven days, confirming a consolidation phase following an impressive rally in recent months. Over three months, however, the stock still maintains a gain of 37.65%, supported by a bullish momentum that has propelled the price well above its reference moving averages. The 50-day moving average, located at 22.16 euros, and the 200-day moving average, at 14.62 euros, remain significantly below the current price, indicating the strength of the upward movement initiated in recent quarters. The RSI, at 54, is positioned in a neutral zone, signaling that the stock is neither overbought nor oversold after today's correction. The nearest technical resistance is at 33.50 euros, a level the price did not manage to reach during the recent bullish push. This threshold now represents a milestone to be crossed for the trend to regain lasting momentum.

Market Environment and Sector Performance

Friday's session took place in a highly nervous atmosphere on European stock markets. The CAC 40 dropped 1.40% during the session, while the SBF 120 lost 1.39%. The volatility measured by the VIX, which increased by over 12% in its last update to 25.09 points, reflects a high level of tension on the global markets. In the healthcare sector, comparable stocks also suffered. Sanofi dropped 0.46% and UCB fell by 2.10%, though to a much lesser extent than Nanobiotix. The Paris-based medtech, specializing in nanotechnology applied to oncology, shows a monthly volatility of 28.12%, making it more sensitive to market movements. Its very low beta, at 0.05, however, indicates that historically the stock largely moves independently of major indices, which relativizes the observed pull effect this Friday.